ecancermedicalscience
Published: 20/04/2010 12:11:48

Results of a Phase IIb study, presented at the American Association for Cancer Research 101st Annual Meeting 2010, showed a clear clinical benefit from trabedersen, a TGF-beta inhibitor, in patients with high-grade glioma; the Phase III study SAPPHIRE (NCT00761280) is currently enrolling.

"Current therapies for this patient population include surgery, radiation and chemotherapy with temozolomide," said...

admin

Pregnant Woman Undergoes “Kinder, Gentler” Brain Surgery at Saint John’s Health Center Neuroscience Institute by Surgeons Using Brain Port Device

April 19, 2010 10:00 AM Eastern Daylight Time

SANTA MONICA, Calif.--(BUSINESS WIRE)--A unique device developed to make brain surgery easier and less traumatic has been successfully used on a patient who was pregnant and suffering from a potentially life-threatening brain cyst. The device, called a “Brain Port,” was pioneered by...

admin

EurekAlert!
Source: McGill University

Public release date: 15-Apr-2010
Contact: William Raillant-Clark
william.raillant-clark@mcgill.ca
514-398-2189
McGill University

International Cancer Genome Consortium plans to sequence 25,000 cancer genomes

This press release is available in French.

A new network was announced today by the International Cancer Genome Consortium (ICGC), and Dr. Bartha Knoppers, Director of the...

admin

HemOnc Today
Posted December 4, 2009

A retrospective analysis of patients treated for pediatric cancers indicated that Ewing’s sarcoma and astrocytoma were the types most likely to recur within 20 years.

Researchers reviewed data collected on 12,795 patients, of whom 806 experienced recurrence five or more years after diagnosis. The median age at original diagnosis was 8.3 years; it was 26 years at follow-up. Most late recurrences occurred five to 10 years following...

admin

Pioneering study may open door to first targeted treatment for common childhood brain tumour

Insciences
Published on 16 April 2009, 05:58


Scientists have found evidence to suggest that ‘small molecule’ drugs could offer the first effective chemotherapy for childhood low-grade astrocytomas, improving the prognosis for hundreds diagnosed with the disease – reveals research published today in The Journal of Pathology.

The team of British and American...

admin